title: Study design and rationale of "a multicenter, open-labeled, randomized controlled trial comparing three 2nd-generation drug-eluting stents in real-world practice" (CHOICE trial).
abstract: BACKGROUND
  The second-generation drug-eluting stents (DES) have shown superiority in many studies relating to safety and efficacy when compared with the first-generation DES. However, it is unclear whether there are differences in efficacy and safety among the second-generation DES after long-term follow-up.
  
  
  METHODS
  This multicenter, prospective, randomized, open-labeled trial will directly compare the efficacy and safety among the patients treated with either everolimus-eluting stent (EES), zotarolimus-eluting stent with biolinx polymer (ZES-R), or biolimus-eluting stent (BES) with minimal exclusion criteria. The primary end point is a patient-oriented composite consisted of cardiac death, myocardial infarction not clearly attributable to a nontarget vessel and clinically indicated target lesion revascularization at 24-month clinical follow-up post-index procedure. With the hypothesis that "BES is non-inferior to EES" or "BES is non-inferior to ZES-R" in primary end point, approximately 2,600 patients will be assigned to one of the types of stents using a web-based randomization system.
  
  
  CONCLUSIONS
  The CHOICE trial will directly compare the efficacy and safety of EES, ZES-R, and BES in everyday clinical practice for long-term follow-up.
authors.affiliation: Division of Cardiology, Yonsei University Wonju Christian Hospital, Wonju, South Korea.
authors.forename: Young Jin
authors.initials: YJ
authors.lastname: Youn
authors.forename: Jun-Won
authors.initials: JW
authors.lastname: Lee
authors.forename: Sung Gyun
authors.initials: SG
authors.lastname: Ahn
authors.forename: Seung-Hwan
authors.initials: SH
authors.lastname: Lee
authors.forename: Hyun Hee
authors.initials: HH
authors.lastname: Choi
authors.forename: Hyunmin
authors.initials: H
authors.lastname: Choi
authors.forename: Cheol Ung
authors.initials: CU
authors.lastname: Choi
authors.forename: Jin Bae
authors.initials: JB
authors.lastname: Lee
authors.forename: Jang Hyun
authors.initials: JH
authors.lastname: Cho
authors.forename: Tae Soo
authors.initials: TS
authors.lastname: Kang
authors.forename: Byung Ryul
authors.initials: BR
authors.lastname: Cho
authors.forename: Kwang Soo
authors.initials: KS
authors.lastname: Cha
authors.forename: Moo Hyun
authors.initials: MH
authors.lastname: Kim
authors.forename: Min Su
authors.initials: MS
authors.lastname: Hyon
authors.forename: Sang-Sig
authors.initials: SS
authors.lastname: Cheong
authors.forename: Do-Sun
authors.initials: DS
authors.lastname: Lim
authors.forename: Kyoo Rok
authors.initials: KR
authors.lastname: Han
authors.forename: Myung Ho
authors.initials: MH
authors.lastname: Jeong
authors.forename: Keum Soo
authors.initials: KS
authors.lastname: Park
authors.forename: Junghan
authors.initials: J
authors.lastname: Yoon
mesh_terms: D000328:Adult; D000465:Algorithms; D003327:Coronary Disease / Q000401:mortality / Q000628:therapy; D054855:Drug-Eluting Stents / Q000009:adverse effects; D000068338:Everolimus; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000628:therapy*; D011474:Prosthesis Design; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000068338:Everolimus; C489443:zotarolimus; C518022:umirolimus; D020123:Sirolimus